The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for risdiplam (Evrysdi), the first treatment that can be given ...
Oral function should be measured routinely to determine individual bulbar involvement stages in spinal muscular atrophy (SMA). “Our results underscore the heterogeneity of oral function effort across ...
Spinal muscular atrophy is a disease that robs people of physical strength by affecting the motor nerve cells in the spinal cord, taking away the ability to walk, eat, or breathe. It is the number one ...
The FDA approved the drug on August 7, and on August 17, the European Medicines Agency (EMA) accepted the marketing authorization application for the spinal muscular atrophy (SMA) treatment. Spinal ...
EMA has recommended that Evrysdi be granted marketing authorization in the EU for the treatment of patients with certain types of SMA. The European Medicines Agency (EMA) has issued its recommendation ...
For now, Roche’s oral spinal muscular atrophy (SMA) drug is too costly to gain the go ahead from England’s drug-price watchdogs. The National Institutes for Health and Care Excellence (NICE) published ...
Global drug major Roche has launched 'Evrysdi' (Risdiplam) in India for the treatment of Spinal Muscular Atrophy (SMA). As per the company, Evrysdi is the first and only approved treatment available ...
Roche's oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on the NHS in England, after NICE reached a three-year access agreement with the ...
LOS ANGELES – An orally administered investigational drug increased protein levels in babies with spinal muscular atrophy (SMA) type 1, according to trial data to be reported here next week. The new ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...
Roche's oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on the NHS in England, after NICE reached a three-year access agreement with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results